Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 42

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 42
---
 of the scope or duration of the patents directed to our drug candidates, all of which could limit
our ability to stop others from using or commercializing similar or identical drug candidates or technology to compete directly with us,
without payment to us, or result in our inability to manufacture or commercialize drug candidates or approved products (if any) without
infringing third-party patent rights. In addition, if the breadth or strength of the claims of our patents and patent applications is
threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current
or future drug candidates, or could have a material adverse effect on our ability to raise funds necessary to continue our research programs
or clinical trials. Such proceedings also may result in substantial cost and require significant time from our scientists and management,
even if the eventual outcome is favorable to us.

In addition, given the amount of time required
for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly
after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others
from commercializing products or technology similar or identical to ours for a meaningful amount of time, or at all. Moreover, some of
our licensed patents and owned or licensed patent applications may in the future be co-owned with third parties. If we are unable to obtain
exclusive licenses to any such co-owners’ interest in such patents or patent applications, such co-owners may be able to license
their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In
addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties, and such cooperation
may not be provided to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations
and prospects.

Further, we rely on a combination of trade secrets,
know-how, technology and nondisclosure, and other contractual agreements and technical measures to protect our rights in the technology.
If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor,
our business and financial condition could be materially and adversely affected. The laws of some foreign countries do not protect our
proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary
rights in